MARKET

BTX

BTX

Brooklyn Immunotherapeutics Inc
NASDAQ
0.2444
-0.0068
-2.71%
After Hours: 0.2490 +0.0046 +1.88% 19:56 09/29 EDT
OPEN
0.2600
PREV CLOSE
0.2512
HIGH
0.2600
LOW
0.2401
VOLUME
310.32K
TURNOVER
0
52 WEEK HIGH
10.10
52 WEEK LOW
0.2100
MARKET CAP
14.38M
P/E (TTM)
-0.1162
1D
5D
1M
3M
1Y
5Y
BRIEF-Brooklyn Immunotherapeutics Inc- On Sept 9, Co Entered Into A Master Services Agreement With Factor Bioscience Inc.
BRIEF-Brooklyn Immunotherapeutics Inc- On Sept 9, Co Entered Into A Master Services Agreement With Factor Bioscience Inc.
Reuters · 09/15 20:44
Brooklyn ImmunoTherapeutics Discloses Agreement With Factor Bioscience
Brooklyn ImmunoTherapeutics Discloses Agreement With Factor Bioscience
MT Newswires · 09/15 16:58
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers SenesTech (NASDAQ:SNES) stock rose 28.0% to $0.64 during Thursday's after-market session. The market value of their outstanding shares is at $7.8 million.
Benzinga · 09/01 21:40
Swiss stocks - Factors to watch on August 19
Swiss stocks - Factors to watch on August 19
Reuters · 08/19 04:45
Brooklyn ImmunoTherapeutics releases head and neck cancer phase 2 trial results
A phase 2 trial of Brooklyn ImmunoTherapeutics' (NASDAQ:BTX...
Seekingalpha · 07/26 14:33
Brooklyn ImmunoTherapeutics Shares Tick lower After Data From Head and Neck Cancer Study
Brooklyn ImmunoTherapeutics Inc (NASDAQ: BTX) has announced results from the INSPIRE Phase 2 trial of IRX-2 in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity. The study's primary endpoint was to estimate 2-ye...
Benzinga · 07/26 13:49
Brooklyn ImmunoTherapeutics Announces Results Of Phase 2 Study Of IRX-2 In Head And Neck Cancer
Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients
Benzinga · 07/26 11:37
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagn...
GlobeNewswire · 07/26 11:30
More
About BTX
Brooklyn ImmunoTherapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The Company also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.

Webull offers kinds of Brooklyn Immunotherapeutics Inc stock information, including NASDAQ:BTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BTX stock methods without spending real money on the virtual paper trading platform.